𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Nitazoxanide plus pegylated interferon and ribavirin in the treatment of genotype 4 chronic hepatitis C, a randomized controlled trial

✍ Scribed by Shehab, Hany M.; Elbaz, Tamer M.; Deraz, Dalia M.

Book ID
126839038
Publisher
John Wiley and Sons
Year
2013
Tongue
English
Weight
167 KB
Volume
34
Category
Article
ISSN
0106-9543

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Randomized controlled trial of pegylated
Randomized controlled trial of pegylated interferon-alfa 2a and ribavirin in treatment-naive chronic hepatitis C genotype 6
✍ Khoa D. Lam; Huy N. Trinh; Son T. Do; Thuan T. Nguyen; Ruel T. Garcia; Tuan Nguy πŸ“‚ Article πŸ“… 2010 πŸ› John Wiley and Sons 🌐 English βš– 246 KB πŸ‘ 2 views

Hepatitis C virus (HCV) genotype is an important criteria in determining duration of therapy and predictor of sustained virologic response (SVR) to pegylated interferon (PEG IFN) and ribavirin (RBV) therapy. Optimal duration of therapy for patients with HCV genotype 6 is not known. We conducted a mu

Interleukin 28B polymorphism predicts pe
Interleukin 28B polymorphism predicts pegylated interferon plus ribavirin treatment outcome in chronic hepatitis C genotype 4
✍ Stella De Nicola; Alessio Aghemo; Maria Grazia Rumi; Enrico Galmozzi; Luca Valen πŸ“‚ Article πŸ“… 2012 πŸ› John Wiley and Sons 🌐 English βš– 499 KB πŸ‘ 1 views

Single nucleotide polymorphisms (SNPs) near the interleukin 28B (IL28B) region are the strongest baseline predictors of a sustained virologic response (SVR) to peg-interferon (PegIFN) and ribavirin (Rbv) in patients with hepatitis C virus (HCV) genotype 1 infection. Whether this holds true for HCV-4